Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO (AR, JR); Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO (SLC).
J Addict Med. 2021;15(3):252-254. doi: 10.1097/ADM.0000000000000738.
Buprenorphine is highly effective for the treatment of opioid use disorder and is increasingly being used in the treatment of chronic pain. For various reasons, patients on buprenorphine may request discontinuation of this medication. Tapering off buprenorphine can be challenging due to intolerable withdrawal symptoms, including nausea, malaise, anxiety, and dysphoria. A single dose of extended-release buprenorphine may facilitate discontinuation of buprenorphine by mitigating prolonged, debilitating opioid withdrawal symptoms. We report on three cases of successful transition from low dose sublingual buprenorphine to a single injection of 100 mg extended-release buprenorphine to opioid cessation in patients who had previously been unable to taper fully off buprenorphine. This novel use of extended-release buprenorphine provides a viable alternative to fully transition patients off buprenorphine when they are medically and emotionally ready.
丁丙诺啡对于治疗阿片类药物使用障碍非常有效,并且越来越多地被用于治疗慢性疼痛。由于各种原因,正在使用丁丙诺啡的患者可能会要求停止使用这种药物。由于难以忍受的戒断症状,包括恶心、不适、焦虑和烦躁,逐渐减少丁丙诺啡的剂量具有挑战性。单次给予丁丙诺啡缓释片可能会通过减轻长时间、使人衰弱的阿片类戒断症状,有助于停止丁丙诺啡的使用。我们报告了三例成功的病例,这些患者此前无法完全停用丁丙诺啡,他们从低剂量舌下丁丙诺啡过渡到单次注射 100 毫克丁丙诺啡缓释片,从而成功停用阿片类药物。当患者在医学和情感上都准备好完全停用丁丙诺啡时,这种丁丙诺啡缓释片的新用途为他们提供了一种可行的替代方案。